Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib in Intraductal Pancreatic Mucinous Neoplasms
NCT00482625Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jun 2007
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in intraductal papillary mucinous neoplasm (IPMN), sponsored by National Cancer Institute. Primary endpoint: Reduction in Number of Positive IPMN Cells and Staining Intensity After Treatment. Started Jun 2007; status: terminated.
02
Drugs
erlotinib
03
Conditions
intraductal papillary mucinous neoplasm (IPMN)
Beyond the preview
Go deeper on NCT00482625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00482625.